Chimerix (Seattle, WA) is applying its technology to the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration, has closed $23.1M in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures.

TechniScan Medical Systems (Salt Lake City, UT) developer of ultrasound technology for breast imaging raised $6.4 million in Series D funding from Green and Gold Holdings and private investors.

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.

Glucon (Boulder, CO) developer of a blood glucose measurement system raised an undisclosed amount of Series D funding. The deal was led by the 3i Group and was joined by Sequel Venture Partners, Quest Capital Partnership, Hunt Ventures and previous investors Aurum Ventures, Giza Venture Capital, MKI, Infinity Venture Capital Fund and Ascend Technology Ventures.

Blue Heron Biotechnology (Bothell, WA) a provider of gene synthesis services raised approximately $3.7M in Series D funding. Participants include Crabtree Ventures, Integra Ventures and Invitrogen.

Pacific Biosciences (Menlo Park, CA) a company focused on DNA gene sequencing, has raised approximately $50M in Series D funding. The financing was led by Maverick Capital and included by return backers Alloy Ventures, Kleiner Perkins and Mohr Davidow Ventures.